Home » Stocks » STRO

Sutro Biopharma, Inc. (STRO)

Stock Price: $20.01 USD -1.34 (-6.28%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 918.30M
Revenue (ttm) 42.72M
Net Income (ttm) -32.13M
Shares Out 32.57M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $20.01
Previous Close $21.35
Change ($) -1.34
Change (%) -6.28%
Day's Open 21.17
Day's Range 19.16 - 20.99
Day's Volume 439,662
52-Week Range 7.06 - 28.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre...

3 days ago - PRNewsWire

SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein en...

1 week ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre...

3 weeks ago - PRNewsWire

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 18, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre...

1 month ago - PRNewsWire

Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...

2 months ago - PRNewsWire

Sutro is a leader in CFPS and has major collaborations to prove it. Its early data is a lethal late line cancer is very promising.

3 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

4 months ago - PRNewsWire

iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and th...

Other stocks mentioned: CMD, IBIO
4 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

4 months ago - PRNewsWire

One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.

4 months ago - The Motley Fool

Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutro Biopharm...

Other stocks mentioned: BCRX, MRNA, LLY
4 months ago - Benzinga

Sutro Biopharma (STRO) is on the rise Friday with heavy trading of STRO stock despite the company not announcing anything new today. The post Sutro Biopharma: 7 Things for STRO Stock Investors to Know A...

4 months ago - InvestorPlace

Sutro Biopharma Inc. (NASDAQ: STRO) made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.

4 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Execu...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

5 months ago - PRNewsWire

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXGT, AXP, JPM, KO, MCD, MRK ...
6 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

8 months ago - PRNewsWire

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -1.69% and 7.66%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

Sutro Biopharma (NASDAQ: STRO) shares are trading lower on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating and an $18 price target.

9 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., June 22, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

10 months ago - PRNewsWire

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: AGIO, JNCE, MRSN
10 months ago - The Motley Fool

SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein eng...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietar...

11 months ago - PRNewsWire

Sutro Biopharma: Revenue-Generating Platform Positioned For Growth

11 months ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Sutro Biopharma

1 year ago - Zacks Investment Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 16.88% and 21.22%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Sutro Biopharma's Platform Technology Makes It A Promising Oncology Pick For 2020

1 year ago - Seeking Alpha

About STRO

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate rec... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
CEO
William Newell
Employees
191
Stock Exchange
NASDAQ
Ticker Symbol
STRO
Full Company Profile

Financial Performance

In 2020, STRO's revenue was $42.72 million, a decrease of -0.03% compared to the previous year's $42.74 million. Losses were -$32.13 million, -42.37% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price forecast is 31.83, which is an increase of 59.07% from the latest price.

Price Target
$31.83
(59.07% upside)
Analyst Consensus: Strong Buy